Haijiao Yan

566 total citations
23 papers, 466 citations indexed

About

Haijiao Yan is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Haijiao Yan has authored 23 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Haijiao Yan's work include MicroRNA in disease regulation (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Circular RNAs in diseases (4 papers). Haijiao Yan is often cited by papers focused on MicroRNA in disease regulation (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Circular RNAs in diseases (4 papers). Haijiao Yan collaborates with scholars based in China and United States. Haijiao Yan's co-authors include Wensong Liu, Jingting Jiang, Xiao Zheng, Mei Ji, Jun Wu, Yufang Zuo, Wenlin Huang, Jiangxue Wu, Changping Wu and Xiao Xu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Haijiao Yan

20 papers receiving 458 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haijiao Yan China	11	343	302	128	35	33	23	466
Margit Riis Norway	10	389 1.1×	256 0.8×	117 0.9×	48 1.4×	24 0.7×	16	513
Zanxi Fang China	10	262 0.8×	203 0.7×	63 0.5×	42 1.2×	27 0.8×	18	363
Matthew F. Jones United States	10	304 0.9×	283 0.9×	104 0.8×	22 0.6×	18 0.5×	13	463
Luxi Qian China	13	317 0.9×	258 0.9×	62 0.5×	41 1.2×	17 0.5×	25	423
Ge Lou China	12	302 0.9×	182 0.6×	146 1.1×	54 1.5×	49 1.5×	13	493
Xun Zhu China	10	492 1.4×	421 1.4×	79 0.6×	45 1.3×	27 0.8×	16	610
Breanna M. Javier United States	4	168 0.5×	186 0.6×	219 1.7×	39 1.1×	27 0.8×	4	323
Yichao Wang China	12	346 1.0×	358 1.2×	81 0.6×	50 1.4×	27 0.8×	27	491
Zhongcheng Huang China	12	294 0.9×	293 1.0×	177 1.4×	41 1.2×	62 1.9×	23	481
Zhang Cao China	11	268 0.8×	156 0.5×	87 0.7×	20 0.6×	52 1.6×	20	369

Countries citing papers authored by Haijiao Yan

Since Specialization

Citations

This map shows the geographic impact of Haijiao Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haijiao Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haijiao Yan more than expected).

Fields of papers citing papers by Haijiao Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haijiao Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haijiao Yan. The network helps show where Haijiao Yan may publish in the future.

Co-authorship network of co-authors of Haijiao Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Haijiao Yan. A scholar is included among the top collaborators of Haijiao Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haijiao Yan. Haijiao Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yan, Haijiao, et al.. (2025). IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma. Cancer Biotherapy and Radiopharmaceuticals. 40(1). 78–88.

Zhang, Ye, et al.. (2024). The Tumor Immune Microenvironment plays a Key Role in Driving theProgression of Cholangiocarcinoma. Current Cancer Drug Targets. 24(7). 681–700. 4 indexed citations

Cheng, Gang, Yong Chen, Nong Xu, et al.. (2024). Safety and efficacy of mecapegfilgrastim in preventing neutropenia in patients with head and neck cancer: a multicenter, prospective, observational, real-world study. Translational Cancer Research. 13(12). 6895–6904.

Deng, Qian, et al.. (2023). Circulating tumor cells in gastric cancer: developments and clinical applications. Clinical and Experimental Medicine. 23(8). 4385–4399. 3 indexed citations

Ma, Jun, Huiqiang Huang, Peifen Fu, et al.. (2021). Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Annals of Translational Medicine. 9(10). 893–893. 2 indexed citations

Huang, Huiqiang, Zengjun Li, Gang Cheng, et al.. (2021). Prophylaxis of Neutropenia with Mecapegfilgrastim in Patients with Hematologic Malignancies. Blood. 138(Supplement 1). 4569–4569.

Chen, Wenyu, et al.. (2021). Circulating tumor DNA detection and its application status in gastric cancer: a narrative review. Translational Cancer Research. 10(1). 529–536. 12 indexed citations

Zhou, Wenjie, Qi Wang, Chen Wu, et al.. (2021). m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1. Journal of Oncology. 2021. 1–11. 24 indexed citations

Li, Xiaodong, et al.. (2020). PD-L1 for gallbladder cancer: case report. Translational Cancer Research. 9(5). 3742–3749. 1 indexed citations

10.

Yan, Haijiao, et al.. (2020). Value of Plasma Methylated SFRP2 in Prognosis of Gastric Cancer. Digestive Diseases and Sciences. 66(11). 3854–3861. 19 indexed citations

11.

Liu, Wensong, et al.. (2020). MicroRNA-708 inhibits the proliferation and chemoresistance of pancreatic cancer cells. Biocell. 44(1). 73–80. 7 indexed citations

12.

Yan, Haijiao, Wenyu Chen, Xiaodong Li, et al.. (2020). Association of dynamic changes of methylated SFRP2 in ctDNA with prognosis in advanced gastric cancer.. Journal of Clinical Oncology. 38(15_suppl). e15051–e15051. 1 indexed citations

13.

Yan, Haijiao, Qing Li, Jun Wu, et al.. (2017). MiR-629 promotes human pancreatic cancer progression by targeting FOXO3. Cell Death and Disease. 8(10). e3154–e3154. 43 indexed citations

14.

Liu, Wensong, Feng Zhu, Yong Jiang, et al.. (2012). siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Oncology Reports. 29(3). 1183–1188. 32 indexed citations

15.

Yan, Haijiao, Wensong Liu, Wenhui Sun, et al.. (2012). miR-17-5p Inhibitor Enhances Chemosensitivity to Gemcitabine Via Upregulating Bim Expression in Pancreatic Cancer Cells. Digestive Diseases and Sciences. 57(12). 3160–3167. 48 indexed citations

16.

Jiang, Jingting, Xiao Zheng, Xiao Xu, et al.. (2011). Prognostic Significance of miR-181b and miR-21 in Gastric Cancer Patients Treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS ONE. 6(8). e23271–e23271. 69 indexed citations

17.

Zuo, Yufang, Jiangxue Wu, Zumin Xu, et al.. (2011). Minicircle-oriP-IFNγ: A Novel Targeted Gene Therapeutic System for EBV Positive Human Nasopharyngeal Carcinoma. PLoS ONE. 6(5). e19407–e19407. 20 indexed citations

18.

Yan, Haijiao, et al.. (2010). Predictive and Prognostic Value of Smac, VEGF and Ki67 Expression in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics. 78(3). S197–S197. 1 indexed citations

19.

Yan, Haijiao, Jiangxue Wu, Wensong Liu, et al.. (2010). MicroRNA-20a Overexpression Inhibited Proliferation and Metastasis of Pancreatic Carcinoma Cells. Human Gene Therapy. 21(12). 1723–1734. 59 indexed citations

20.

Liu, Wensong, Haijiao Yan, Renyi Qin, et al.. (2008). siRNA Directed Against Survivin Enhances Pancreatic Cancer Cell Gemcitabine Chemosensitivity. Digestive Diseases and Sciences. 54(1). 89–96. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact